Herantis Pharma - Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson's disease

Core Insights - Herantis Pharma Plc has announced promising biomarker data from its Phase 1b trial of HER-096, indicating a biological response in patients with Parkinson's disease [2][3][4] Group 1: Clinical Trial Results - The Phase 1b trial involved 24 patients with Parkinson's disease, who received either HER-096 or a placebo twice weekly over four weeks, generating over 2.5 million datapoints for analysis [6][7] - The biomarker data demonstrated significant shifts in disease-relevant pathways, including proteostasis, mitochondrial function, and neuroinflammation, aligning with the expected mechanism of action for HER-096 [5][9] Group 2: Future Development Plans - The encouraging results from the Phase 1b trial support the advancement of HER-096 into a Phase 2 clinical trial planned for 2026, aimed at evaluating efficacy, safety, and tolerability in early-stage Parkinson's patients [10] - The data will inform dose selection and clinical endpoint refinement for future studies, as well as guide the prioritization of biomarkers for confirmation in subsequent trials [7][8] Group 3: Company Statements - Antti Vuolanto, CEO of Herantis, emphasized that the biomarker evidence de-risks the program for potential partners and investors, reinforcing confidence in the long-term value of HER-096 [4] - Henri Huttunen, CSO of Herantis, noted that the findings provide translational evidence of biologically meaningful changes, consistent with preclinical data, and strengthen the therapeutic rationale for HER-096 as development progresses [5]